Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Clears IND for RiboX's RXIM002, Circular RNA CAR-T for ITP

9 August 2026 · By · Wire by Fusion42

Published

9 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

The FDA granted IND clearance to RiboX Therapeutics for RXIM002, a circular RNA CAR-T therapy for immune thrombocytopenia, accepting Chinese trial data and allowing an accelerated dose-titration and subcutaneous formulation, potentially simplifying CAR-T administration.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You must rethink cell therapy trial design as the FDA now trusts foreign data to accelerate US approval and accepts outpatient, injectable CAR-T. Your manufacturing and trial logistics are about to simplify, and clinical endpoints must prove immune reset, not just symptom control.

◆ Coverage

2 sources · 9 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcar-tfda-indcircular-rnaautoimmuneclinical-trialin-vivo